OncoMyx Therapeutics and Avery Therapeutics will be presenting at BIO CEO.Continue reading
Author Archive: AZBio
A Path for Hope: Startup pursues first regenerative treatment for Alzheimer’s disease
“Starting up NeuTherapeutics is so exciting because we are creating the path to bring the first regenerative therapeutic for Alzheimer’s disease to those who need it. We believe that treatment with allo will restore brain function and independence for patients,” says Dr. Roberta Brinton, a Regents Professor of pharmacology and neurology and a member of the BIO5 Institute.
Meet Zoey – AZBio’s Social Media and Communications Intern
Zoey Leipsic joined the AZBio Team in January of 2022 as our Social Media and Communications Intern. In her role, Zoey collects the latest news from our AZBio Member Companies and shares it via posts on AZBio.org as well as on AZBio’s social media accounts so that more people can learn about the important work you do.Continue reading
Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
Paris, February 3, 2022. Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.Continue reading
Perkins Coie Office Hours for AZBio
Perkins Coie attorneys are available to answer questions or discuss legal challenges pertaining to intellectual property and corporate issues that may arise for AZBio Members during “AZBio Office Hours”
President Biden Reignites Cancer Moonshot to End Cancer as We Know It
Biden-Harris Administration Sets Goal of Reducing Cancer Death Rate by at least 50 Percent Over the Next 25 Years, and Improving the Experience of Living with and Surviving Cancer
AZBio Welcomes New Board Members in 2022
The Arizona Bioindustry Association Board of Directors elected five new directors to its leadership team at its January 2022 meeting. The AZBio Board directs the organization’s key actions and strategies as it pursues its vision of making Arizona a Top-Ten Bioscience State.
Medtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management aloneContinue reading
Arizona State University Biodesign Institute receives three new grants totaling $5.2 million to advance the fight against Parkinson’s disease
The Michael J. Fox Foundation has awarded three new grants totaling $5.2 million to Arizona State University (ASU) to explore three pioneering treatments for Parkinson’s disease (PD).
The awards will fund research led by Principal Investigator Dr. Jeffrey H. Kordower, each targeting underlying causes of the disease, which currently affects nearly 1 million people in the U.S. alone.
The new projects focus on two primary hallmarks of PD: the loss of dopamine-producing neurons in the brain and the accumulation within nerve cells of a misfolded form of the protein alpha-synuclein (α-syn).
Preparing to deliver next-generation therapeutics
Mayo Clinic is among the academic medical centers on the cusp of biomanufacturing next-generation cell and gene therapies that offer hope of new cures for rare and complex diseases. Biomanufacturing this new era of biologic medicines is much different than manufacturing pharmaceuticals from complex molecules. It requires highly specialized lab infrastructure, new processes and new scientific know-how.
A couple of Mayo Clinic-led papers encompass some of the first studies to probe how hospital facilities are handling the growing demand for cell and gene therapies that are being tested in clinical trials.Continue reading